Potassium Ion

Potassium Ion

SCHEMBL3683077

Fc1ccc([B-](c2ccc(F)cc2)(c2ccc(F)cc2)c2ccc(F)cc2)cc1.[K+]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
ACHE P22303 1/20 0.40
IDO1 P14902 3/20 0.35
ORAI1 Q96D31 1/20 0.35
ORAI2 Q96SN7 1/20 0.35
ORAI3 Q9BRQ5 1/20 0.35
TRPV6 Q9H1D0 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.35
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP13 P45452 1/20 0.33
NFE2L2 Q16236 2/20 0.32
TAAR1 Q96RJ0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL689497 0.97 CA1 (0.42) CA1CA2CA7CA9ACHE
Silver SCHEMBL1451626 0.93 CA1 (0.40) CA1CA2CA7CA9ACHE
SCHEMBL912936 0.93 CA1 (0.40) CA1CA2CA7CA9ACHE
Water SCHEMBL16539351 0.93 CA1 (0.40) CA1CA2CA7CA9ACHE
SCHEMBL6430652 0.93 CA1 (0.40) CA1CA2CA7CA9ACHE
SCHEMBL623289 0.93 CA1 (0.40) CA1CA2CA7CA9ACHE
Lithium Ion SCHEMBL1451658 0.93 CA1 (0.40) CA1CA2CA7CA9ACHE
Water SCHEMBL2688804 0.90 CA1 (0.38) CA1CA2CA7CA9ACHE
Silver SCHEMBL9414258 0.90 CA1 (0.38) CA1CA2CA7CA9ACHE
Water SCHEMBL17686587 0.90 CA1 (0.38) CA1CA2CA7CA9ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024196901-A2 A HIGH THROUGHPUT ION-SENSING METHOD WHITESIDES GEORGE M (US) 2024-09-26 WO claimed
US-20150119848-A1 METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2015-04-30 US claimed
EP-2856133-A1 IMPROVED METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION The University of Tennessee Research Foundation (US) 2015-04-08 EP claimed
WO-2013180814-A1 IMPROVED METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-12-05 WO claimed
EP-3629928-B1 METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE THE UNIV OF TENNESSEE RESEARCH FOUNDATION (US) 2025-11-05 EP disclosed
WO-2024196901-A2 A HIGH THROUGHPUT ION-SENSING METHOD WHITESIDES GEORGE M (US) 2024-09-26 WO disclosed
US-11686722-B2 Compositions and methods to detect molecules in a sample INFUSENSE CORP. (US) 2023-06-27 US disclosed
US-11375929-B2 Method and device for detection of bioavailable drug concentration in a fluid sample THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2022-07-05 US disclosed
EP-3629928-A1 METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE The University of Tennessee Research Foundation (US) 2020-04-08 EP disclosed
US-20190331656-A1 COMPOSITIONS AND METHODS TO DETECT MOLECULES IN A SAMPLE INFUSENSE CORP. 2019-10-31 US disclosed
EP-3555609-A1 COMPOSITIONS AND METHODS TO DETECT MOLECULES IN A SAMPLE Infusense Corp. (US) 2019-10-23 EP disclosed
WO-2018222820-A1 METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION IN A FLUID SAMPLE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2018-12-06 WO disclosed
US-20150119848-A1 METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2015-04-30 US disclosed
EP-2856133-A1 IMPROVED METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION The University of Tennessee Research Foundation (US) 2015-04-08 EP disclosed
WO-2013180814-A1 IMPROVED METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-12-05 WO disclosed
US-7671210-B2 Process for production of optically active cyclopropanecarboxylate compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-02 US disclosed
EP-1783130-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND SUMITOMO CHEMICAL CO (JP) 2009-12-30 EP disclosed
US-20090048450-A1 Process for production of optically active cyclopropanecarboxylate compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-19 US disclosed
EP-1783130-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-05-09 EP disclosed
EP-0617277-A1 Ion-selective electrode and process for preparing the same HITACHI, LTD. (JP) 1994-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048450-A1 Process for production of optically active cyclopropanecarboxylate compound CBR3, C9, CBR1 CA1 659/4885CA2 199/4885CA7 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.